“hemophilia-a” Archives

in
Entry Author Date Location
Freeline Therapeutics and Checkmate Pharma Make Opening IPO Moves 07/21/20 Europe
CSL Behring Bolsters Hemophilia Lineup With Deal for uniQure’s Gene Therapy 06/25/20 Philadelphia
Regeneron Pays Intellia $100M to Add Hemophilia to CRISPR R&D Pact 06/01/20 New York
Generation Bio Leads a Trio of Biotech Companies Aiming for the Nasdaq 05/22/20 National
Generation Bio Pockets $110M for Next Wave of Gene Therapy, IPO Plans 01/13/20 Boston
Bio Roundup: So Long Celgene, RNAi’s Arrival, Pharma in 2020 & More 11/22/19 National
Bio Roundup: Opioids in Court, IPO Parade, Brain Cancer Bet & More 05/31/19 National
With Sliver of Data, BioMarin to Seek OK for Hemophilia Gene Therapy 05/28/19 San Francisco
Roche Bets $4.8B on Spark Therapeutics and the Future of Gene Therapy 02/25/19 National
Bio Roundup: Nobel Prizes, Duchenne Steps, Guardant’s IPO & More 10/05/18 National
FDA Approves Roche Drug For All Hemophilia A Patients, But Rivals Loom 10/04/18 San Francisco
Bio Roundup: Pfizer’s Rare Results, U.K.’s CAR-T No, IPO Go-Go & More 08/31/18 National
Data Could Make Roche Drug a Hemophilia Standard, But for How Long? 05/21/18 San Francisco
Pandion Raises $58M to Bring Cancer-Fighting Tactics to Immune Disorders 01/18/18 Boston
In Week of Hemophilia News, Alnylam Drug Cleared to Move Forward 12/15/17 Boston
Gene Therapy Advances, But Hemophilia Is No Easy Target 12/13/17 National
Bio Roundup: Trials to Watch, Mega Deals, Video Game Therapy & More 12/08/17 Boston
FDA Approves Genentech Hemophilia Drug, But Adds Safety Warning 11/16/17 San Francisco
RegenxBio to Acquire Dimension Tx in Combo of Gene Therapy Companies 08/25/17 Boston
Bio Roundup: PDUFA Progress, BCRA Redux, CAR-T Thumbs Up, & More 07/14/17 National
Genentech’s Hemophilia Drug Slashes Bleeding Rates, Early Data Show 06/26/17 San Francisco
Shire Steps Back in Hemophilia Gene Therapy Race, Scraps Baxalta Drug 08/03/16 Boston
At Big Hemophilia Meeting, More Data, and Promise, For Gene Therapy 07/28/16 National
West Coast Bio Roundup: Prince, Theranos, Second Genome, CytomX & More 04/22/16 San Francisco
With BioMarin Data, Gene Therapy Finally Shows Impact on Hemophilia A 04/20/16 San Francisco
Biogen R&D Chief Doug Williams Leaves to Run New Cancer Startup 07/10/15 Boston
Gene Therapy’s Rebirth Continues With Bristol, UniQure Cardio Deal 04/06/15 New York
Stop the Bleeding: Can Gene Therapy Finally Cure Hemophilia? 03/23/15 National
Biogen Places Gene Therapy Bet in Crowded Hemophilia Space 01/29/15 Boston
East Coast Biotech Roundup: Bluebird, Moderna, Navitor, & More 06/20/14 Boston
Page 1 of 2 next page »